Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 258

1.

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A.

Cancer Res. 2006 Aug 15;66(16):8109-15.

2.

Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy.

Hay T, Jenkins H, Sansom OJ, Martin NM, Smith GC, Clarke AR.

Cancer Res. 2005 Nov 15;65(22):10145-8. Erratum in: Cancer Res. 2006 Jan 1;66(1):599.

3.

Therapeutic exploitation of tumor cell defects in homologous recombination.

Powell SN, Kachnic LA.

Anticancer Agents Med Chem. 2008 May;8(4):448-60. Review.

PMID:
18473729
4.

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency.

McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A.

Cancer Biol Ther. 2005 Sep;4(9):934-6. Epub 2005 Sep 1.

PMID:
16251802
5.

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.

Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T.

Nature. 2005 Apr 14;434(7035):913-7. Erratum in: Nature. 2007 May 17;447(7142):346.

6.

Inhibition of homologous recombination by treatment with BVDU (brivudin) or by RAD51 silencing increases chromosomal damage induced by bleomycin in mismatch repair-deficient tumour cells.

Vernole P, Muzi A, Volpi A, Dorio AS, Terrinoni A, Shah GM, Graziani G.

Mutat Res. 2009 May 12;664(1-2):39-47. doi: 10.1016/j.mrfmmm.2009.02.005. Epub 2009 Feb 21.

PMID:
19428379
7.

Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.

Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson SJ, Drew Y, Kyle S, Los G, Hostomsky Z, Edmondson RJ, Curtin NJ.

Clin Cancer Res. 2010 Apr 15;16(8):2344-51. doi: 10.1158/1078-0432.CCR-09-2758. Epub 2010 Apr 6.

8.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A.

Nature. 2005 Apr 14;434(7035):917-21.

9.

Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination.

Schultz N, Lopez E, Saleh-Gohari N, Helleday T.

Nucleic Acids Res. 2003 Sep 1;31(17):4959-64.

10.

Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.

Yap TA, Sandhu SK, Carden CP, de Bono JS.

CA Cancer J Clin. 2011 Jan-Feb;61(1):31-49. doi: 10.3322/caac.20095. Epub 2011 Jan 4. Review.

11.
12.

Inhibition of poly(ADP-ribose)polymerase does not affect the recombination events in CHO xrs6 and wild type cells.

Wojewódzka M, Kruszewski M, Ołdak T, Bartłomiejczyk T, Goździk A, Szumiel I.

Radiat Environ Biophys. 2006 Nov;45(4):277-87. Epub 2006 Sep 12.

PMID:
16967295
13.

Involvement of poly(ADP-ribose) polymerase in base excision repair.

Dantzer F, Schreiber V, Niedergang C, Trucco C, Flatter E, De La Rubia G, Oliver J, Rolli V, Ménissier-de Murcia J, de Murcia G.

Biochimie. 1999 Jan-Feb;81(1-2):69-75. Review.

PMID:
10214912
14.

Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?

Shall S, de Murcia G.

Mutat Res. 2000 Jun 30;460(1):1-15. Review.

PMID:
10856830
15.

Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.

Cavallo F, Graziani G, Antinozzi C, Feldman DR, Houldsworth J, Bosl GJ, Chaganti RS, Moynahan ME, Jasin M, Barchi M.

PLoS One. 2012;7(12):e51563. doi: 10.1371/journal.pone.0051563. Epub 2012 Dec 12.

16.

Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition.

Krawczyk PM, Eppink B, Essers J, Stap J, Rodermond H, Odijk H, Zelensky A, van Bree C, Stalpers LJ, Buist MR, Soullié T, Rens J, Verhagen HJ, O'Connor MJ, Franken NA, Ten Hagen TL, Kanaar R, Aten JA.

Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9851-6. doi: 10.1073/pnas.1101053108. Epub 2011 May 9.

17.

Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly(ADP-ribose) polymerase (PARP) inhibitor treatment.

Pan MR, Hsieh HJ, Dai H, Hung WC, Li K, Peng G, Lin SY.

J Biol Chem. 2012 Feb 24;287(9):6764-72. doi: 10.1074/jbc.M111.287037. Epub 2012 Jan 4.

18.

Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.

Kyle S, Thomas HD, Mitchell J, Curtin NJ.

Br J Radiol. 2008 Oct;81 Spec No 1:S6-11. doi: 10.1259/bjr/99111297.

PMID:
18820000
19.

Inducing synthetic lethality using PARP inhibitors.

Boss DS, Beijnen JH, Schellens JH.

Curr Clin Pharmacol. 2010 Aug;5(3):192-5. Review.

PMID:
20406170
20.

[Cellular functions of BRCA genes - from basic science to therapeutics].

Miki Y.

Gan To Kagaku Ryoho. 2012 Apr;39(4):498-501. Japanese.

PMID:
22504671

Supplemental Content

Support Center